{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:36:28Z","timestamp":1790876188055,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fentanyl is a synthetic opioid fueling the current opioid crisis in the United States. While emergency department (ED) visits due to opioid-related overdoses, injection complications, and withdrawals become increasingly more frequent, fentanyl is not detected in routine toxicology testing. We evaluated 2 FDA-approved fentanyl immunoassays in a sampled ED population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>De-identified, remnant urine specimens (n = 213) collected from patients presenting to a large ED were analyzed using ARK Fentanyl II (ARK II) and Immunalysis SEFRIA (SEFRIA) fentanyl immunoassays on an Architect c16000 (Abbott) analyzer. All discrepant specimens were evaluated by LC-MS\/MS. Additionally, polysubstance abuse patterns and trends were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While intra-assay imprecision was comparable for ARK II and SEFRIA, inter-assay imprecision for ARK II and SEFRIA varied from 8.0% to 1.8% and from 37% to 12.5%, respectively. SEFRIA had a marginally higher false-positivity rate (3%) than ARK II (1%). Both assays had equivalent sensitivity of 95%, with ARK II (99%) having greater specificity than SEFRIA (97%). Fentanyl was detected in 13.7% of drug-panel-positive patient samples and most frequently observed in patients also testing positive for amphetamines and cocaine. Notably, fentanyl was detected in 5.3% of patient samples that were negative for all other drugs in our standard toxicology panel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A sizable portion of drug-positive samples from our ED were positive for fentanyl, with a subset of patients testing positive for fentanyl alone. Implementation of fentanyl testing into routine toxicology panels can elucidate polysubstance abuse paradigms and capture ED patients that would go undetected in standard panels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfae022","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T01:09:05Z","timestamp":1709600945000},"page":"886-894","source":"Crossref","is-referenced-by-count":4,"title":["Performance of Fentanyl Immunoassays in an ED Patient Population"],"prefix":"10.1093","volume":"9","author":[{"given":"Catherine M","family":"Mills","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical University of South Carolina , Charleston, SC 29425 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker C","family":"Dryja","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical University of South Carolina , Charleston, SC 29425 , United States"},{"name":"Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina , Charleston, SC 29425 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Champion-Lyons","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical University of South Carolina , Charleston, SC 29425 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Keppler","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical University of South Carolina , Charleston, SC 29425 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8317-3382","authenticated-orcid":false,"given":"Nikolina","family":"Babic","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical University of South Carolina , Charleston, SC 29425 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"2024090311500104100_jfae022-B1","first-page":"1","article-title":"National hospital care survey demonstration projects: mortality following nonfatal opioid overdose visits to the emergency department","volume":"187","author":"Spencer","year":"2023","journal-title":"Natl Health Stat Report"},{"key":"2024090311500104100_jfae022-B2","author":"Maucione"},{"key":"2024090311500104100_jfae022-B3","first-page":"38","article-title":"A practical guide to urine drug monitoring","volume":"35","author":"Raouf","year":"2018","journal-title":"Fed Pract"},{"key":"2024090311500104100_jfae022-B4","author":"Dezman"},{"key":"2024090311500104100_jfae022-B5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.15585\/mmwr.mm6923a3","article-title":"Notes from the field: high prevalence of fentanyl detected by the Maryland Emergency Department Drug Surveillance System\u2014Baltimore, Maryland, 2019","volume":"69","author":"Dezman","year":"2020","journal-title":"MMWR Morb Mortality Wkly Rep"},{"key":"2024090311500104100_jfae022-B6","first-page":"1","article-title":"Estimates of drug overdose deaths involving fentanyl, methamphetamine, cocaine, heroin, and oxycodone: United States, 2021","volume":"27","author":"Spencer","year":"2023","journal-title":"Vital Stat Surveillance Rep"},{"key":"2024090311500104100_jfae022-B7","author":"Little"},{"key":"2024090311500104100_jfae022-B8","author":"Maryland General Assembly"},{"key":"2024090311500104100_jfae022-B9","author":"Bill Track 50"},{"key":"2024090311500104100_jfae022-B10","author":"Pennsylvania General Assembly"},{"key":"2024090311500104100_jfae022-B11","author":"Brooks"},{"key":"2024090311500104100_jfae022-B12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.annemergmed.2021.04.023","article-title":"Consensus recommendations on the treatment of opioid use disorder in the emergency department","volume":"78","author":"Hawk","year":"2021","journal-title":"Ann Emerg Med"},{"key":"2024090311500104100_jfae022-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2015.01.003","article-title":"The cost-effectiveness of alcohol screening, brief intervention, and referral to treatment (SBIRT) in emergency and outpatient medical settings","volume":"53","author":"Barbosa","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"2024090311500104100_jfae022-B14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MLR.0b013e3181bd498f","article-title":"Evaluation of the Washington state screening, brief intervention, and referral to treatment project: cost outcomes for Medicaid patients screened in hospital emergency departments","volume":"48","author":"Estee","year":"2010","journal-title":"Med Care"},{"key":"2024090311500104100_jfae022-B15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13722-018-0117-1","article-title":"Emergency department screening and interventions for substance use disorders","volume":"13","author":"Hawk","year":"2018","journal-title":"Addict Sci Clin Pract"},{"key":"2024090311500104100_jfae022-B16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MLR.0000000000000859","article-title":"Screening, brief intervention, and referral to treatment in the emergency department: an examination of health care utilization and costs","volume":"56","author":"Pringle","year":"2018","journal-title":"Med Care"},{"key":"2024090311500104100_jfae022-B17","doi-asserted-by":"crossref","first-page":"109195","DOI":"10.1016\/j.drugalcdep.2021.109195","article-title":"Emergency Department Drug Surveillance (EDDS) hospital\u2019s urinalysis results compared with expanded re-testing by an independent laboratory, a pilot study","volume":"230","author":"Schwartz","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2024090311500104100_jfae022-B18","author":"ARK fentanyl II assay [package insert]"},{"key":"2024090311500104100_jfae022-B19","author":"SEFRIA fentanyl urine enzyme immunoassay [product insert]"},{"key":"2024090311500104100_jfae022-B20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"2024090311500104100_jfae022-B21","author":"CDC"},{"key":"2024090311500104100_jfae022-B22","author":"National Center for Drug Abuse Statistics"},{"key":"2024090311500104100_jfae022-B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clinbiochem.2023.01.001","article-title":"Detection of 58 fentanyl analogs using ARK fentanyl II and immunalysis fentanyl immunoassays","volume":"113","author":"Williams","year":"2023","journal-title":"Clin Biochem"},{"key":"2024090311500104100_jfae022-B24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jat\/bkaa053","article-title":"Performance of two fentanyl immunoassays against a liquid chromatography-tandem mass spectrometry method","volume":"45","author":"Feng","year":"2021","journal-title":"J Anal Toxicol"},{"key":"2024090311500104100_jfae022-B25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/jalm\/jfab033","article-title":"Performance evaluation of an automated fenantyl immunoassay","volume":"6","author":"Tang","year":"2021","journal-title":"J Appl Lab Med"},{"key":"2024090311500104100_jfae022-B26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/dta.2382","article-title":"Detectability of fentanyl and designer fentanyls in urine by 3 commercial fentanyl immunoassays","volume":"10","author":"Helander","year":"2018","journal-title":"Drug Test Anal"},{"key":"2024090311500104100_jfae022-B27","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010\u20132021","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"key":"2024090311500104100_jfae022-B28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2024090311500104100_jfae022-B29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12954-023-00782-1","article-title":"Attitudes and experiences with fentanyl contamination of methamphetamine: exploring self-reports and urine toxicology among persons who use methamphetamine and other drugs","volume":"20","author":"Daniulaityte","year":"2023","journal-title":"Harm Reduct J"},{"key":"2024090311500104100_jfae022-B30","doi-asserted-by":"crossref","first-page":"109398","DOI":"10.1016\/j.drugalcdep.2022.109398","article-title":"Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021","volume":"234","author":"Palamar","year":"2022","journal-title":"Drug Alcohol Depend"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/9\/5\/886\/59001253\/jfae022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/9\/5\/886\/59001253\/jfae022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T09:49:33Z","timestamp":1725356973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/9\/5\/886\/7633519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,22]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfae022","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,22]]}}}